Church & Dwight Co., Inc. - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 27, 2008. Church & Dwight Co., Inc. is a large accelerated filer incorporated in Delaware, operating primarily in the consumer products sector through three reportable segments: Consumer Domestic, Consumer International, and Specialty Products Division (SPD). The company manufactures and sells household and personal care products, including brands such as ARM & HAMMER, TROJAN, and Orajel (acquired subsequent to the period).
Key Financial Metrics
| Metric | Three Months Ended June 27, 2008 |
Six Months Ended June 27, 2008 |
|---|---|---|
| Net Sales | $593.96 million | $1,146.83 million |
| Gross Profit | $242.48 million | $466.59 million |
| Gross Margin | 40.8% | 40.7% |
| Net Income | $45.77 million | $101.96 million |
| Diluted EPS | $0.66 | $1.46 |
| Operating Cash Flow | N/A | $130.34 million |
| Total Debt | $739.7 million | $739.7 million |
| Cash & Equivalents | $255.9 million | $255.9 million |
| Net Debt | $483.8 million | $483.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8.7% in the quarter and 8.1% for the six-month period compared to 2007. Growth was driven by higher prices (approx. 5% in Q2), higher unit volume (approx. 3% in Q2), and favorable foreign exchange rates.
- Margin Expansion: Gross margin improved by 110 basis points in Q2 to 40.8%, attributed to product concentration (liquid laundry detergent), manufacturing synergies, and price increases, partially offset by higher commodity costs.
- Expense Increases: Marketing expenses rose 19.7% in Q2 due to increased spending on key brands (ARM & HAMMER, TROJAN). SG&A expenses increased due to foreign exchange, higher R&D, and stock option expenses.
- Debt Reduction: Total debt decreased from $856.0 million at year-end 2007 to $739.7 million, driven by the repayment of $100 million in accounts receivable securitization and term loan repayments.
Outlook, Risks, and Unusual Items
- Subsequent Acquisition: On July 7, 2008, the company acquired Del Pharmaceuticals (Orajel brand) for $380.3 million, funded by $250 million in new bank debt and cash.
- Plant Relocation: The company announced plans to close its North Brunswick, NJ facility and build a new $150 million plant in York County, PA. This will incur approximately $11 million in cash exit costs and $21 million in non-cash accelerated depreciation.
- Convertible Debentures: The company announced the redemption of its $99.9 million 5.25% Senior Convertible Debentures due August 15, 2008, at 101.50% of principal.
- Legal Proceedings: The company won a patent infringement suit against Abbott Laboratories, with damages doubled to $29.2 million (pre-interest) by the District Court, though a post-trial motion remains pending.
- Regulatory Risk: Ongoing FDA discussions regarding labeling for condoms containing nonoxynol-9 (N-9) could impact sales if restrictive rules are promulgated.
- Impairment Charges: The company recorded $5.6 million in asset impairment charges in the Consumer International segment and $3.4 million in tradename impairments in Q1 2008.
Investor Verification Checklist
- Verify the impact of the $380.3 million Orajel acquisition on future leverage ratios and cash flow.
- Monitor the execution and cost overruns of the $150 million York County, PA facility construction.
- Assess the outcome of the pending post-trial motion in the Abbott Laboratories litigation regarding the $29.2 million award.
- Review the company's ability to maintain gross margins amidst rising commodity and energy costs.
- Confirm the successful redemption or conversion of the $99.9 million convertible debentures in August 2008.